Removable Surface BCI Expands Eligibility

Precision is betting that surgery choice, not just decoding performance, will decide who gets a BCI. Its Layer 7 array sits on the brain surface instead of sending threads into tissue, and it is designed to be removed, which makes it easier to fit into familiar neurosurgical workflows like mapping and monitoring. That can widen the pool beyond patients willing to accept a permanent, tissue penetrating implant, and it gives hospitals a lower friction path to adopt the system first in temporary use.

• The product tradeoff is clear. Neuralink places 1,024 electrodes on flexible threads inside brain tissue, which can support higher fidelity signals for fine control, but requires a robot guided intracortical implantation. Precision is aiming for a safer and more reversible profile by staying on the cortical surface.
  2 sacra 3 neuralink 6 neuralink
• Synchron shows why invasiveness matters commercially. Its Stentrode is implanted through a blood vessel with no open brain surgery, and its pitch centers on lowering the surgical hurdle. Precision occupies the middle ground, more invasive than endovascular delivery, but less committal than permanently embedded intracortical threads.
  4 sacra 7 synchron 8 synchron
• The temporary device already gives Precision an adoption wedge. FDA 510(k) clearance in March 2025 covers use on the brain surface for up to 30 days, and the Medtronic StealthStation integration plugs it into operating rooms where surgeons already do navigation guided cranial procedures.
  1 sacra 5 globenewswire 9 everyticker

The next step is turning temporary neurosurgical use into a chronic wireless implant that keeps the same low commitment value proposition. If Precision can preserve removability while adding durable home use for paralysis, it can define a large segment of the BCI market around surgeon acceptance and patient comfort, rather than only raw signal performance.